在患有脑的患者中开始服用抗发作药物
Victoria M Nielsen1, Michael Klompas2,3, Justin Manjourides1
1Department of Public Health and Health Sciences, Northeastern University, Boston, Massachusetts.
JAMA network open
|August 1, 2025
概括
抗发作药物 (ASM) 在脑幸存者中没有显著降低风险. 这项研究发现,在开始ASM的患者和没有开始ASM的患者之间,发病率没有统计学上显著的差异.
科学领域:
- 神经学 神经学
- 临床流行病学 临床流行病学
背景情况:
- 是脑之后经常出现的并发症.
- 抗发作药物 (ASM) 预防脑后的疗效尚不清楚.
研究的目的:
- 研究开始抗发作药物 (ASM) 与脑幸存者的发病风险之间的关联.
主要方法:
- 使用美国商业保险索赔数据 (2016-2022) 的回顾性队列研究.
- 用克隆-传感器-重量方法进行的目标试验模拟与在45天内启动ASM相比,没有启动.
- 权重的卡普兰-梅尔模型评估了风险在90,135和180天后脑.
主要成果:
- 这项研究包括572名脑幸存者 (平均年龄为61.5岁,61.7%是男性).
- 总的来说,22.5%的患者在180天的随访期间患上了.
- 在ASM治疗组和对照组之间在任何时间点都没有观察到风险的统计学上显著差异.
结论:
- 开始服用抗发作药物 (ASM) 与脑幸存者的风险降低无关.
- 需要进一步的研究来验证这些发现,并探索替代性预防策略.
更多相关视频
相关概念视频
Antiepileptic Drugs: Calcium Channel Blockers
603
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
603
Antiepileptic Drugs: Sodium Channel Blockers
861
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
861
Epilepsy and Seizures: Overview
274
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
274
Antiepileptic Drugs: GABAergic Pathway Potentiators
632
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
632
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
439
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
439
Antiepileptic Drugs: Glutamate Antagonists
509
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
509


